Revenue Breakdown
Composition ()
No data
Revenue Streams
Ginkgo Bioworks Holdings Inc (DNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cell Engineering, accounting for 75.7% of total sales, equivalent to $29.38M. Another important revenue stream is Biosecurity. Understanding this composition is critical for investors evaluating how DNA navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Ginkgo Bioworks Holdings Inc maintains a gross margin of 67.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -227.14%, while the net margin is -207.93%. These profitability ratios, combined with a Return on Equity (ROE) of -50.02%, provide a clear picture of how effectively DNA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, DNA competes directly with industry leaders such as SNDA and EHAB. With a market capitalization of $558.64M, it holds a significant position in the sector. When comparing efficiency, DNA's gross margin of 67.04% stands against SNDA's 100.00% and EHAB's 46.40%. Such benchmarking helps identify whether Ginkgo Bioworks Holdings Inc is trading at a premium or discount relative to its financial performance.
